S. Korea To Triple Support For Embryonic Stem Cell Research
This article was originally published in PharmAsia News
Executive Summary
South Korea plans to triple funding for embryonic stem cell research in an effort to boost the ability of local biotechnology companies to establish intellectual property rights. The increase, scheduled over the next five years, would raise the national budget for the research to nearly $100 million. The administration said it was concerned research in the country had declined too much in the wake of fraudulent action by an internationally known South Korean scientist. That case led to a three-year ban on the research, lifted in April. About 20 research laboratories are to share in the increased budget over the next two years. (Click here for more
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.